Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Cases of Peritoneal Carcinomatosis that Require Nephrectomy
Archivos Espanoles de Urologia, cilt.78, sa.8, ss.1002-1008, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 78 Sayı: 8
- Basım Tarihi: 2025
- Doi Numarası: 10.56434/j.arch.esp.urol.20257808.131
- Dergi Adı: Archivos Espanoles de Urologia
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, DIALNET
- Sayfa Sayıları: ss.1002-1008
- Anahtar Kelimeler: cytoreductive surgery, nephrectomy, peritoneal carcinomatosis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been popular surgical treatment approaches for peritoneal carcinomatosis over the past three decades. In addition to metastases due to intra-abdominal malignancies, retroperitoneal renal metastases may occur. This study aimed to evaluate the safety and feasibility of performing nephrectomy in selected patients who underwent CRS for peritoneal carcinomatosis, without increasing morbidity and mortality, and to determine its effect on overall survival (OS). Methods: In this single-centre retrospective observational study, 11 cases that required partial/total nephrectomy were reviewed amongst patients who underwent CRS and HIPEC for peritoneal carcinomatosis between 2017 and 2024. The effects of the surgical procedure on postoperative OS, mortality and morbidity were evaluated. Results: The average age of the patients was 54 years (range: 23–83 years). Peritoneal carcinomatosis was caused by colon carcinoma in four cases, sarcomatosis in two cases, renal cell cancer in two cases, ovarian carcinoma in one case, mesothelioma in one case and teratomatosis in one case. Right nephrectomy was performed in six cases, right partial nephrectomy in three cases, left nephrectomy in one case and bilateral nephrectomy in one case. The average Peritoneal Cancer Index was 22.2, and complete cytoreduction was achieved in 90.9% of the patients. No 30-day mortality was observed. The average OS was 14 months (range: 2–53 months). The 1-year survival rate was 45.4%, the 2-year survival rate was 18% and the 3-year survival rate was 9%. Conclusions: In cases of peritoneal carcinomatosis that require nephrectomy, CRS combined with HIPEC can be performed to achieve complete cytoreduction without increasing morbidity and mortality.